Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ecopetrol SA (EC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Ecopetrol SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Ecopetrol SA trades at $15.69 (market cap $29.34B). The key difference: Ecopetrol SA is far larger — about 35.5× Amphastar Pharmaceuticals Inc's market cap, and Ecopetrol SA pays a 4.17% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EC | |
|---|---|---|
Market Cap | $826.08M | $29.34B |
Sector | Health | Energy |
52-Week High | $30.81 | $16.58 |
52-Week Low | $16.87 | $8.29 |
Enterprise Value | $1.22B | $57.13B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Ecopetrol (EC) trades at $15.58, up 1.23% with bullish technical signals from moving averages. The stock shows mixed fundamentals with declining revenue from $159.6B in 2022 to $119.7B in 2025, though maintains stable 8.76% net margins. Recent corporate developments include a $0.66 dividend payment and S&P credit rating affirmation at BB- with stable outlook as of June 17, 2026.
EC presents a cautious opportunity with attractive valuation multiples (P/E 11.1, P/S 0.97) but faces revenue headwinds. Analyst consensus is mixed with 27% buy ratings and $14.63 target below current price. Key risks include energy price volatility and execution challenges amid declining cash flows from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
